

CLL SOCIETY


Smart Patients Get Smart Care™

Is There Good News Ahead? Update on Omicron and Beyond Available Therapies for COVID-19

March 18, 2022

10 AM PT, 11 AM MT
12 PM CT, 1 PM ET

This program was made
possible by grant support
from




CLL SOCIETY

REGENERON



Speakers



CLL SOCIETY



Welcome

Robyn Brumble, MSN, RN

Director of Scientific Affairs and
Research
CLL Society



Speaker

Joshua A. Hill, MD

Assistant Professor
Vaccine and Infectious Disease Division
and Clinical Research Division
Fred Hutch



Moderator

Brian Koffman, MDCM (retired)
MS Ed

Executive Vice President and
Chief Medical Officer
CLL Society




Speaker

Sameer Parikh, MD, MBBS

Assistant Professor of Medicine,
Hematology
Consultant, Division of Hematology
Mayo Clinic


Poll Questions



CLL SOCIETY



Where to Find the COVID-19 Action Plan On CLL Society's Website



CLL SOCIETY

Translate: Select Language Sign Up in f t Q Search Dr. Brian Koffman's Blog

CLL SOCIETY Smart Patients Get Smart Care™

Home Basics Beyond The Basics Living Well With CLL Clinical Trials Conference Coverage News About Us

COVID-19 UPDATES

Test Before Treat CLL Society Expert Access Program Support Group Event Calendar For Providers: CLL/SLL Toolkit

THE POWER TO HELP FIGHT CLL/SLL MAY BE WITHIN YOU

Discover a clinical study researching an investigational CAR T therapy for CLL and SLL.

TRANSCEND

LEARN MORE

Register Now! CLL Society's COVID-19 Virtual Community Meeting: The Delta Variant and Staying Protected on September 24th

Register Now! CLL Society Ed Forum: The Right Tests at the Right Time on October 15th

CLL Society Support Group meetings will be held virtually due to the threat of coronavirus. Please see our calendar for more details.

What's New in CLL?

ASH 2020: Dr. Neil Kay on Targeting AXL Receptors with TP-0903 to Enhance CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)

Translate: Select Language Sign Up in f t Q Search Dr. Brian Koffman's Blog

CLL SOCIETY Smart Patients Get Smart Care™ Donate to CLL Society

Home Basics Beyond The Basics Living Well With CLL Clinical Trials Conference Coverage CAR-T Support Groups/Education News About Us

COVID-19

This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerges.

The prevalence of coronavirus is growing quickly. Our compromised immune status mandates that we stay well-informed in order to get the best possible care, should we become infected.

The CLL Society will provide frequent medically curated updates and news, both general and specific, to our community in this space until the crisis has passed.

COVID-19 ACTION PLAN

Checklists for Chronic Lymphocytic Leukemia (CLL)
Preparing for Pre and Post COVID-19 Exposure

Register Now! CLL Society's COVID-19 Virtual Community Meeting: The Delta Variant and Staying Protected on September 24th


Latest Update: Recent Publications of Interest for CLL Patients Related to COVID-19

CLL Society Official Statements COVID-19 Updates Managing COVID-19 Re-Entry

When appropriate, the CLL Society will be posting updates and background information on the project.

Watch this expert video series as Dr. Koffman speaks with CLL doctors on topics such as educating the

Recent Updates to the COVID-19 Action Plan Include Links To:



CLL SOCIETY

- The CDC guidance for those who are immunocompromised to remain up-to-date on recommended COVID-19 vaccination dosages.
- A locator tool that will help you find doses of available Evusheld and oral antivirals such as Paxlovid near you.
- A new monoclonal antibody locator tool to locate infusion centers that provide the monoclonal antibody therapies (mAbs) recommended for treatment of COVID-19 (dependent upon the current variant).

NEWS

mAbs should be given within 7 days


Molnupiravir is usually a last choice

COVID-19 PLANNING CHECKLIST	
To Complete Prior To Exposure (Please Reference the Instructions Document)	
Obtain Necessary Supplies and Keep Them on Hand	<input type="checkbox"/> Oxygen Monitoring Device <input type="checkbox"/> High-Quality N95 Masks <input type="checkbox"/> Digital Thermometer(s) <input type="checkbox"/> Rapid Antigen COVID-19 Home Tests <input type="checkbox"/> Over-the-Counter Medications <input type="checkbox"/> Miscellaneous Household Items
Remain Up-To-Date on COVID-19 Vaccination Series	<input type="checkbox"/> Dose#1 Date: _____ <input type="checkbox"/> Dose#2 Date: _____ <input type="checkbox"/> Dose#3 Date: _____ <input type="checkbox"/> Dose#4 Date: _____ <input type="checkbox"/> Additional Dose Date: _____ <input type="checkbox"/> Additional Dose Date: _____
Obtain Pre-Exposure Prophylaxis (Evusheld)	<input type="checkbox"/> Dose#1 Date: _____ <input type="checkbox"/> My Next Dose of Evusheld is Due: _____
Know Where to Go for COVID-19 Testing	<input type="checkbox"/> Name of Testing Location: _____ <input type="checkbox"/> Ensure Testing Facility Will Perform BOTH the Rapid Test & the PCR Test
Determine Where All Critical COVID-19 Treatments Are Available Nearby	<input type="checkbox"/> Antiviral Pills: _____ <input type="checkbox"/> IV Antiviral Injection: _____ <input type="checkbox"/> Monoclonal Antibodies: _____
Healthcare Team Contact Information	<input type="checkbox"/> CLL Provider's Contact Info: _____ <input type="checkbox"/> Create a List of All Healthcare Providers and Place in the Planning Folder
Personal Paperwork to Place in COVID-19 Planning Folder	<input type="checkbox"/> List of All Medications, Vitamins, and Supplements <input type="checkbox"/> Copy of Living Will, Power of Attorney, Physician Orders for Life-Sustaining Treatment, and Advance Directive <input type="checkbox"/> Copy of Insurance Cards (Front and Back)
CLL Society Documents to Place in COVID-19 Planning Folder	<input type="checkbox"/> CLL Society's Official Statement for Prioritizing CLL Patients Emergency Room Care Related to COVID-19 <input type="checkbox"/> Print CLL Society's Pre-COVID Exposure Planning Document
Household Isolation and Quarantine Plan	<input type="checkbox"/> Have a Discussion with Everyone Living Inside the Home to Help Them Gain An Understanding About How to Isolate or Quarantine As Well

Visit CLLSociety.org/COVID-19 for More Information

(Last Updated January, 2022)


Test to Treat: Faster, Easier Access to Life-Saving COVID-19 Treatments



CLL SOCIETY

- Launches today 3/18/2022.
- Nationwide Test to Treat initiative gives individuals an important way to rapidly access free lifesaving treatment for COVID-19.
- Able to get tested and – if they are positive and treatments are appropriate for them – receive a prescription from a health care provider, and have their prescription filled all in one location.
- Don't need to be tested at the site. Can use home test result.
- Still able to get prescription with a HCPs order at other pharmacies.

<https://aspr.hhs.gov/TestToTreat/Pages/default.aspx>



CLL SOCIETY


Smart Patients Get Smart Care™

Prevention and Treatment for COVID-19

Dr. Josh Hill, MD
Vaccine and Infectious Diseases
Division
Fred Hutchinson Cancer
Research Center

March 18, 2022

COVID-19 Risk Framework



CLL SOCIETY

Age

<30

30-49

50-69

≥70

Comorbidity

e.g., diabetes,
obesity, CKD,
pregnancy, lung
disease

None

1

2

3+

Vaccination Status

Full vaccination
plus boosting

Full vaccination

Partial
vaccination

Unvaccinated

Immunosuppression

None

Steroids

Lymphodepletion (eg Rituximab)

Solid organ transplant

Anti-metabolites (eg mycophenolate)


AIDS

Active heme malignancy/BMT


Consider exposure risks and societal/structural risk factors

Courtesy of Dr. William Werbel

Therapeutic Landscape for COVID-19




CLL SOCIETY



COVID-19 Outpatient Therapeutics

Clinical Decision Aid for Ages 12+

Adult or pediatric patient (ages 12 and older weighing at least 40 kg) with mild to moderate COVID-19 and at high risk for progression to severe disease



References:

¹ NIH's COVID-19 Treatment Guidelines Therapeutic Management of Nonhospitalized Adults With COVID-19. <https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/>

² NIH's COVID-19 Treatment Guidelines Statement on bebtelovimab https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-bebtelovimab/?utm_source=site&utm_medium=home&utm_campaign=highlights

³ Paxlovid EUA. <https://www.fda.gov/media/155050/download>

⁴ NIH's COVID-19 Treatment Guidelines Panel's Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications. <https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-paxlovid-drug-drug-interactions/>

⁵ Sotrovimab EUA. <https://www.fda.gov/media/149534/download>

⁶ Veklury (remdesivir) Prescribing Information. https://www.gilead.com/-/media/files/pdfs/medicines/covid-19/veklury/veklury_pi.pdf

⁷ Bebtelovimab EUA. <https://www.fda.gov/media/156152/download>



⁸ Molnupiravir EUA. <https://www.fda.gov/media/155054/download>




Omicron Subvariant BA.2 is Rapidly Rising in the US



CLL SOCIETY





CLL SOCIETY

Smart Patients Get Smart Care™


Management of CLL

Dr. Sameer Parikh, MD,
MBBS

Division of Hematology
Mayo Clinic
Rochester, MN

March 18, 2022

REVISED COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised




Vaccine	Vaccination Schedule			
Pfizer-BioNTech (ages 5 years and older)	1st dose	2nd dose (21 days after 1 st dose)	3rd dose (at least 28 days after 2 nd dose)	Booster dose* (at least 3 months after 3 rd dose)
Moderna (ages 18 years and older)	1st dose	2nd dose (28 days after 1 st dose)	3rd dose (at least 28 days after 2 nd dose)	Booster dose* (at least 3 months after 3 rd dose)
Janssen (ages 18 years and older)	1st dose	Additional dose† (at least 28 days after 1 st dose)		Booster dose* (at least 2 months after additional dose)

*Any COVID-19 vaccine can be used for the booster dose in people ages 18 years and older, though mRNA vaccines are preferred. For people ages 12–17 years, only Pfizer-BioNTech can be used. People ages 5–11 years should not receive a booster dose.


†Only Pfizer-BioNTech or Moderna COVID-19 Vaccine should be used

SARS-CoV-2 Vaccination in CLL




CLL SOCIETY


Antibody responses to
vaccination in CLL patients:
50%




Antibody response lower in
patients receiving CLL treatment



Third dose of vaccination
improves response in
about 25% patients



Get Vaccinated, But Act Like You're Not



CLL SOCIETY

Questions:

- What does this mean in terms of safe activities?
- What's needed to make CLL patients safer?
- How do patients decide to risk:
 - A family visit or meal?
 - A vacation?
 - A movie or show or concert or sporting event or museum?
 - A restaurant?


Evusheld

Knowns:

- Long-acting monoclonal antibody
- Passive versus active immunity
- For immunocompromised only
 - Who qualifies?


Unknowns:

- Activity against future Variants of Concern
- Length of Action



CLL SOCIETY

Treatment of CLL in 2022



CLL SOCIETY


Treatment Options for CLL:

- Chemoimmunotherapy
- BTK inhibitors (ibrutinib, acalabrutinib, etc.)
- BCL2 inhibitors (venetoclax)
- CD20 monoclonal antibody (rituximab, etc.)
- Combination treatments

Factors to consider prior to treatment:

- Age
- Fitness
- Genomic characteristics of CLL:
 - *IGHV* mutation
 - CLL FISH
- Co-morbidities:
 - Cardiac
 - Renal
- Patient preference:
 - Continuous vs. time limited treatment


COVID-19



CLL SOCIETY

Audience Questions & Answers

This program was made
possible by grant support
from




CLL SOCIETY

REGENERON



Thank You for Attending!



CLL SOCIETY

Please take a moment to complete our **post-event survey**, your feedback is important to us

If your question was not answered, please feel free to email asktheexpert@cllsociety.org

Join us on April 25th for our next webinar, **Health and Wellness: Beyond the Medicine Cabinet**

CLL Society is invested in your long life. Please invest in the long life of the CLL Society by supporting our work

cllsociety.org/donate-to-cll-society/